Targeted Therapy of Osteoarthritis via Intra‐Articular Delivery of Lipid‐Nanoparticle‐Encapsulated Recombinant Human FGF18 mRNA
Advanced Healthcare Materials · 2024-11 · 13 (29)
DOI: 10.1002/adhm.202400804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 04.10.2024. Verfasst von Mengze Sun und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sports Medicine, Institute of Sports Medicine of Peking University, Beijing Key Laboratory of Sports Injuries, Peking University Third …. Hauptthemen laut MEDLINE: Osteoarthritis, Fibroblast Growth Factors, RNA, Messenger, Nanoparticles. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Regional Innovation Joint Fund of the National Natural Science Foundation of China (Integrated Project), Clinical Medicine Plus X-Young Scholars Project of Peking University, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Fibroblast growth factor 18 (FGF18) emerges as a promising therapeutic target for osteoarthritis (OA). In this study, a novel articular cavity‐localized lipid nanoparticle (LNP) named WG‐PL14 is developed. This optimized formulation has a nearly 30‐fold increase in mRNA expression as well as better articular cavity enrichment compared to commercial lipids MC3 when performing intra‐articular injection. Then, a mRNA sequence encoding recombinant human FGF18 (rhFGF18) for potential mRNA therapy in OA is optimized. In vitro assays confirm the translation of rhFGF18 mRNA into functional proteins within rat and human chondrocytes, promoting cell proliferation and extracellular matrix (ECM) synthesis. Subsequently, the therapeutic efficacy of the LNP‐rhFGF18 mRNA complex is systematically assessed in a mouse OA model. The administration exhibits several positive outcomes, including an improved pain response, upregulation of ECM‐related genes (e.g., AGRN and HAS2), and remodeling of subchondral bone homeostasis compared to a control group. Taken together, these findings underscore the potential of localized LNP‐rhFGF18 mRNA therapy in promoting the regeneration of cartilage tissue and mitigating the progression of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sports Medicine, Institute of Sports Medicine of Peking University, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, Beijing, 100191, China.
- Engineering Research Center of Sports Trauma Treatment Technology and Devices, Ministry of Education, Beijing, 100191, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, 100191, China.
- Institute of Orthopedics, The Fourth Medical Center, Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma & War Injuries PLA, No. 28 Fuxing Road…
ORCID-Profile: Mengze Sun, Yun Zhao, Xi Wang, Kai Wang, Xiaoqing Hu
Förderung
- the Regional Innovation Joint Fund of the National Natural Science Foundation of China (Integrated Project)
- Clinical Medicine Plus X-Young Scholars Project of Peking University
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
- Emerging Engineering Interdisciplinary-Young Scholars Project, Peking University
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Sun, M., Ma, B., Pan, Z., Zhao, Y., Tian, L., Fan, Y., Kong, W., Wang, J., Xu, B., Ao, Y., Guo, Q., Wang, X., Peng, X., Li, X., Cheng, J., Miao, L., Wang, K., & Hu, X. (2024). Targeted Therapy of Osteoarthritis via Intra‐Articular Delivery of Lipid‐Nanoparticle‐Encapsulated Recombinant Human FGF18 mRNA. Advanced Healthcare Materials, 13(29). https://doi.org/10.1002/adhm.202400804
Vancouver
Sun M, Ma B, Pan Z, Zhao Y, Tian L, Fan Y, et al. Targeted Therapy of Osteoarthritis via Intra‐Articular Delivery of Lipid‐Nanoparticle‐Encapsulated Recombinant Human FGF18 mRNA. Advanced Healthcare Materials. 2024;13(29). doi:10.1002/adhm.202400804
BibTeX
@article{Sun2024,
author = {Sun, Mengze and Ma, Bin and Pan, Zihang and Zhao, Yun and Tian, Liangliang and Fan, Yifei and Kong, Weijing and Wang, Junyan and Xu, Boyang and Ao, Yingfang and Guo, Quanyi and Wang, Xi and Peng, Xiaohong and Li, Xiaoxia and Cheng, Jin and Miao, Lei and Wang, Kai and Hu, Xiaoqing},
title = {Targeted Therapy of Osteoarthritis via Intra‐Articular Delivery of Lipid‐Nanoparticle‐Encapsulated Recombinant Human FGF18 mRNA},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {29},
doi = {10.1002/adhm.202400804}
}
EUVIMED